Analyst Ratings for Bio-Rad Laboratories Inc. Cl A (BIO)

Updated: 2017-07-29

Shares of Bio-Rad Laboratories Inc. Cl A (NYSE:BIO) have received a consensus rating of Buy from Wall Street analysts. About 30 days ago, BIO was issued an average rating of Overweight.

Of the 4 analysts covering the stock, 3 gave it a buy rating, 1 gave an overweight rating, 0 issued a hold rating, 0 gave an underweight rating, and 0 issued a sell rating. Compared to three months ago, there has been an increase of 2 in the number of analysts with a positive outlook on the stock. Meanwhile, the number of analysts pessimistic about the company has increased by 0.

A number of analysts gave price targets for BIO. The maximum price target given was 275, which equates to a potential upside of 16.35 percent. The most pessimistic analyst gave a price target of 245, implying potential capital losses of 3.66 percent. Some investors take price targets and stock ratings with a grain of salt, knowing that some analysts can have indirect business with the stocks they cover.

Analysts have revised their earnings estimates upwards for this quarter, by about 14.42 percent on average, compared to last month. This can be compared with the average change in earnings estimates over the past 3 months, which is -16.21 percent. On the other hand, earnings estimates for the fiscal year have been revised upwards by 3.5 percent, as compared to a month ago. Expanding the time horizon to 3 months, the average change in fiscal year estimates becomes 6.68 percent.

People are often interested in whether analysts were united in the direction of their revisions. Over the past month, 1 analysts increased their quarterly estimates, while 0 analysts made negative revisions. Also over the last month, 1 analysts increased their estimates for the FY earnings, compared to 0 analysts that revised their FY estimates downwards.

BIO has an estimated earnings growth rate of 215.57 percent as forecasted by analysts. Another measure frequently examined by investors is the PEG ratio. A lower PEG ratio is favorable, because people typically see that as an indicator of higher growth relative to stock price. Many investors consider PEG ratios between 0 and 1 as preferrable, although it is frequently more appropriate to compare PEG ratios to the company's peers. The PEG ratio of BIO is 1.17.

BIO has traded between a high of 239.91 and a low of 143.39 over the past year. Today's price is 64.84 percent above the 52-week low, and 1.48 percent below the high. BIO has a price/earnings ratio of 251.45. Investors typically compare the P/E ratio to a company's peers in the industry. The BIO value stock report compares BIO to some of its peers using value stock charts. The stock has a market capitalization of $7.03 billion. BIO's next earnings release will be on 0000-00-00, which is days away.